优化后的2024版欧洲白血病网络（ELN）风险分层改善了急性髓系白血病（AML）患者接受维奈克拉治疗后的生存预后。
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
作者信息
Lachowiez Curtis A, Ravikumar Vishvaas I, Othman Jad, O'Nions Jenny, Peters Daniel T, McMahon Christine, Swords Ronan, Cook Rachel, Saultz Jennifer N, Tyner Jeffrey W, Dillon Richard, Zeidner Joshua F, Pollyea Daniel A
机构信息
Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
出版信息
Blood. 2024 Dec 26;144(26):2788-2792. doi: 10.1182/blood.2024026925.
The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.
欧洲白血病网（European LeukemiaNet）近期发布了2024年急性髓系白血病患者接受去甲基化药物联合维奈克拉治疗的风险分层指南。该分析表明，在当前模型中重新分类并纳入新的基因突变可进一步改善预后并实现个体化预测。
Zotero 插件